Altimmune Q2 net loss $24.6M; pemvidutide MASH Phase 2b topline due Q1 2025

Altimmune, Inc.

2024-Q2 EPS reported -$0.69 revenue$10,000

Cash, cash equivalents and short-term investments totaled $164.9M as of June 30, 2024.
Net loss for Q2 2024 was $24.6M ($0.35 per share) vs. $16.1M ($0.32 per share) in Q2 2023.
Phase 2b IMPACT trial of pemvidutide in MASH enrollment progressing; topline data expected Q1 2025.
End-of-Phase 2 FDA meeting for obesity program expected late Q3 2024 to discuss Phase 3 design.
Phase 2 MOMENTUM obesity trial showed up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.